Skip to content

Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy

Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03040050
Enrollment
38
Registered
2017-02-01
Start date
2017-01-01
Completion date
2019-07-02
Last updated
2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Therapy, Prostate Biopsy

Brief summary

The study is a randomized controlled trial. Subjects are randomly assigned 1:1 to receive either rapid multiplex qPCR (intervention) prior to standard of care prostate biopsy or standard of care (control) prostate biopsy. The subjects will have a rectal culture swab performed prior to the prostate biopsy. One rectal culture swab will be used for rapid multiplex qPCR and the other swab will be sent to microbiology for a standard culture. The subjects randomized to the intervention group will have the qPCR results shared with the physician to determine if additional standard of care antibiotics are needed at time of standard of care prostate biopsy. The subjects randomized to the control group will not have the qPCR results shared with the physician to determine if additional standard of care antibiotics are needed at time of standard of care prostate biopsy. Approximately, 10 days after the prostate biopsy, the research staff will conduct a chart review and/or telephone call to ask about any prostate biopsy infections and complications.

Interventions

OTHERrPCR results

Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.

OTHERControl group

Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.

Sponsors

The University of Texas Health Science Center at San Antonio
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Investigator)

Masking description

The rPCR results will be provided to the clinical provider for the Interventional group participants. The rPCR results will not be provided to the clinic provider for the control group participants.

Eligibility

Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Be able to give informed consent * Be age 50 or older * Recommended to undergo a prostate biopsy * No allergy or side effect to fluoroquinolone antibiotics * No history of prostate biopsy infection * No hepatic or renal insufficiency in which fluoroquinolone antibiotics are contraindicated.

Exclusion criteria

* Unable to give informed consent * Age \< 50 * Not recommended to have prostate biopsy * Allergic to or have side effects to fluoroquinolone antibiotics * History of prostate biopsy infection * Hepatic or renal insufficiency in which fluoroquinolones antibiotics are contraindicated.

Design outcomes

Primary

MeasureTime frameDescription
Results of rapid qPCR to determine standard of care antibiotic prophylaxis for prostate biopsy.Day of prostate biopsyReduction in dual antibiotic prophylaxis in the intervention vs.usual care groups.

Secondary

MeasureTime frameDescription
Determine if rapid qPCR test results in longer patient wait times.Day of prostate biopsyDifference in the amount of time the PCR technique takes compared to the fastest workflow (physician chooses no additional antibiotics).
Determine if rPCR results and standard rectal culture results are the same.1 weekComparison of rPCR results to standard rectal culture on Fluoroquinolone infused MacConkey agar.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026